We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 28, 2022

Alpelisib Plus Fulvestrant in Patients With HR+, HER2− Advanced Breast Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study
J. Clin. Oncol 2022 Jun 01;40(16_suppl)1006, D Juric, HS Rugo, A Reising, et al

Further Reading